04:37
Briefly, a awful advancing animal breast blight was crude subcutaneoulsy into almsman animals. The animals were advised alert per anniversary for 6 weeks with either BT2111, Herceptin(R) or a placebo. Each anniversary the bump volumes were measured. In the placebo ascendancy animals, the tumors added in admeasurement by 400% over baseline. In both the BT2111 and Herceptin(R) advised groups, the bump advance was absolutely halted. Further, both Herceptin(R) and BT2111 were able-bodied acceptable with no credible signs of toxicity.
"Over the accomplished year the Herceptin(R)-BT2111 conjugate affairs has delivered some aberrant after-effects for biOasis," says Rob Hutchison, CEO. "The abutting basic footfall for us in our BT2111 program, was to appraise its achievement in this blight xenograft study. In this study, we were able to analyze anon the Herceptin(R)-BT2111 conjugate to Herceptin(R) alone. The after-effects demonstate that the Herceptin(R)-BT2111 conjugate is as alive as, and at several timepoints exceeded Herceptin(R), in endlessly bump growth. Herceptin(R) is a potentailly life-saving analysis that reduces the recurrance of HER2+ breast blight amid women adeptness chemotherapy. Unfortunately, this biologic is afar from the academician and is appropriately abortive for alleviative women with academician alteration of HER2+ breast cancer. We accept announed ahead that a ample allotment of intravenously administered Herceptin(R)-BT2111 conjugate enters the accurateness of beginning animals. Our abutting footfall is to authenticate in accord with Texas Tech University that our Herceptin(R)-BT2111 conjugate is active in endlessly the advance of academician metastases of breast cancer." For added advice on this, bang this video articulation "xenograft" on the biOasis home folio - http://www.bioasis.ca/
ABOUT BT2111 - BT2111 is a conjugate amid biOasis' Transcend academician commitment agent and trastuzumab (trade name of Herceptin(R)), a humanized monoclonal antibiotic acclimated clinically in the analysis of HER2+ breast cancer. It is appear that up to 30% of HER2+ breast blight patients advance academician alteration for which ameliorative options are limited. Because of its adeptness to cantankerous the blood-brain barrier, biOasis is researching the abeyant of BT2111 for analysis of HER2+ metastatic breast blight in the brain.
Herceptin(R) is a registered brand of Roche/Genentech.
ABOUT BIOASIS
biOasis Technologies Inc. is a biopharmaceutical aggregation headquartered in Vancouver, Canada. Based on Transcend, biOasis proprietary academician commitment platform, the Aggregation is focused on creating new drugs that can cantankerous the blood-brain barrier to abode unmet medical needs in the analysis of academician diseases such as neurodegeneration, metastatic blight and metabolic diseases. biOasis trades on the TSX Venture Exchange beneath the attribute "BTI". For added advice about the Aggregation please appointment www.bioasis.ca.
Forward-Looking Statements
Certain statements in this columnist absolution accommodate advanced statements aural the acceptation of the Private Balance Litigation Reform Act of 1995 or advanced advice beneath applicative Canadian balance legislation that may not be based on absolute fact, including after limitation statements absolute the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and agnate expressions. Such advanced statements or advice absorb accepted and alien risks, uncertainties and added factors that may account our absolute results, contest or developments, or industry results, to be materially altered from any approaching results, contest or developments accurate or adumbrated by such advanced statements or information. Such factors include, amid others, our date of development, abridgement of any artefact revenues, added basic requirements, accident associated with the achievement of analytic trials and accepting authoritative approval to bazaar our products, the adeptness to assure our bookish property, assurance on collaborative ally and the affairs for negotiating added accumulated collaborations or licensing arrange and their timing. Specifically, assertive risks and uncertainties that could account such absolute contest or after-effects bidding or adumbrated by such advanced statements and advice to alter materially from any approaching contest or after-effects bidding or adumbrated by such statements and advice include, but are not bound to, the risks and uncertainties that: we may not be able to auspiciously advance and access authoritative approval for p97 as a Physician's Aid to Diagnose Alzheimer's, or approaching articles in our targeted accumulated objectives; our approaching operating after-effects are ambiguous and acceptable to fluctuate; we may not be able to accession added capital; we may not be acknowledged in establishing added accumulated collaborations or licensing arrangements; we may not be able to authorize business and the costs of ablution our articles may be greater than anticipated; we accept no acquaintance in bartering manufacturing; we may face alien risks accompanying to bookish acreage matters; we face added antagonism from biologic and biotechnology companies; and added factors as declared in detail in our filings with the Canadian balance authoritative authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to abode disproportionate assurance on such advanced statements and information, which are able in their absoluteness by this cautionary statement. All advanced statements and advice fabricated herein are based on our accepted expectations and we undertake no obligation to alter or amend such forward- attractive statements and advice to reflect consecutive contest or circumstances, except as appropriate by law.
On Behalf of the Board of Directors
Rob Hutchison Chairman & CEO
"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that appellation is authentic in the behavior of the TSX Venture Exchange) accepts albatross for the capability or accurateness of this release."
Post a Comment